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Introduction
Scope, Aims, and Goals
Human exposure to exogenous chemicals,
whether through drinking water, foodstuffs,
personal products, medicines, or occupational
or environmental exposure, is controlled and
regulated at local, national, and international
levels. Control and regulation of chemical sub-
stances are effected through a number of regula-
tory agencies and authorities and are mandated
by legislation. To regulate the use of chemicals
successfully, authorities require suitable infor-
mation concerning likely human health effects.
Traditionally, such information has arisen from
the use of in vivo animal testing. Increasingly,
however, there has been an awareness that test
data may be inadequate, inappropriate, or
incomplete for many chemical substances. An
attractive alternative to the use of animal testing
has been the development of methodology that
enables predictions of effects to be made directly
from chemical structure. Predictions of effects
from chemical structure encompass a broad
range of techniques and methodologies, gener-
ally referred to as quantitative structure–activity
relationships (QSARs).
The assumption that biological activity is
implicit from chemical structure has been
around for well over 100 years. QSARs offer a
process to formalize this knowledge and an
attempt to form some direct relationships
between chemical structures and biological
effects. QSARs enabling prediction of human
health effects have taken many forms. The
approaches used have included numerical
models, true QSARs, and more formalized
expert system approaches.
Our goal here is to review the international
regulatory use of QSARs to predict the health
effects of chemical substances [the international
regulatory use of QSARs to predict ecologic
effects and environmental fate forms the basis
of a second review (Cronin et al. 2003)].
The use of QSARs by a number of regulatory
agencies to prioritize chemicals for testing and
to ﬁll data gaps in risk assessment data sets are
described. Although QSARs are applied by
agencies worldwide, this review focuses upon
their use in North America and in Europe. It
should be emphasized that our purpose is not
to review the use of QSARs per se, but their
regulatory application; further details on this
complex and evolving topic may be obtained
from a recent review by Walker et al. (2002)
and a web-based database developed by the
Organisation for Economic Co-operation and
Development (OECD 2002b). QSARs alone
have been subject to a number of excellent
recent reviews (Cronin 2000; Dearden et al.
1997; Hulzebos et al. 1999; Walker. In press).
Regulations and the Use 
of SARs/QSARs
The European Union. In the European Union
(EU), risk assessment of chemical substances is
driven by the requirements of Commission
Directive 93/67/EEC on Risk Assessment for
New Notified Substances and Commission
Regulation [European Commission (EC)] No.
1488/94 on Risk Assessment for Existing
Substances (EEC 1993a, 1994). To ensure con-
sistency of application of the Environmental
Risk Assessment (ERA) process, in 1996 the
EU produced a comprehensive technical guid-
ance document (TGD) to support the
Directive on New Substances and the
Regulation on Existing Substances (EC 1996).
This document includes a substantial chapter
providing guidance on the use of QSARs in the
ERA process in terms of where they should be
used, how they should be used, and which ones
should be used. Although considerable informa-
tion is provided in the TGD regarding the pre-
diction of ecologic effects and environmental
fate, no formal recommendations are given on
the use of QSARs for the prediction of human
health effects. The TGD is currently being
extensively revised, but the chapter on the use
of QSARs is not included in this revision. The
TGD can be downloaded from the European
Chemicals Bureau (2002).
According to the current EU system of
chemicals legislation, new and existing sub-
stances are not subject to the same testing
requirements, which means that there is a lack
of knowledge about the potential danger repre-
sented by many existing substances. Existing
substances make up about 99% of the total
volume of chemicals on the EU market. To
address this problem, and other shortcomings
of the current EU system, the EC has pro-
posed a new policy on chemicals in which new
and existing substances will be subject to the
same information requirements. In addition,
the new proposals place the burden of per-
forming hazard and risk assessments on indus-
try rather than on the regulatory authorities
(EC 2002). The proposed system is called
REACH (Registration, Evaluation and
Authorisation of Chemicals). It is expected
that a legislative proposal to implement the
new policy will be drafted in 2003. 
When the REACH system is introduced,
it is possible that additional human health
and ecotoxicologic information could be
required for up to 30,100 existing chemicals
that are currently marketed in volumes
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Therefore, QSAR and other computer-based
methods for predicting toxicity are expected
to play an increasingly important role not
only for the priority setting of chemicals that
need further assessment but also for hazard
assessment purposes.
Danish Environmental Protection Agency.
The Danish Environmental Protection Agency
(Danish EPA 2001) has prepared an advisory
list for self-classification of dangerous sub-
stances using QSAR models. Of approximately
47,000 substances examined; 20,624 substances
were identified as requiring classification for
one or more of the following dangerous proper-
ties: acute oral toxicity, sensitization by skin
contact, mutagenicity, carcinogenicity, and
danger to the aquatic environment. The
Danish EPA stated that “the [QSAR] models
used here are now so reliable that they are able
to predict whether a given substance has one or
more of the properties selected with an accu-
racy of approximately 70–85%.” The Danish
EPA has made extensive use of QSARs and has
developed a QSAR database that contains pre-
dicted data on more than 166,000 substances
(OSPAR Commission 2000). A recent publi-
cation from the Danish EPA (Tyle et al. 2001)
reports the use of QSARs for the high– and
medium–production-volume chemicals used
in the EU. The Danish EPA used a suite of
commercially available and proprietary QSARs
for environmental and human health end-
points. The predictions were made off-line and
were stored in a CHEM-X database. The data-
base was searchable by the Chemical Abstract
Service (CAS) number or chemical name.
Only discrete organic chemicals can be stored
in the database. Expert systems such as
MultiCASE (MultiCASE Inc., Beachwood,
OH, USA) and Toxicity Prediction by
Computer-Assisted Technology (TOPKAT;
Accelrys Inc., Cambridge, UK) were used for
the predictions (details noted by endpoint
below).
German Federal Institute for Health
Protection of Consumers and Veterinary
Medicine. In Germany, new chemicals are
notified to the Federal Institute for Health
Protection of Consumers and Veterinary
Medicine (BgVV). To provide a tool for the
evaluation of physicochemical properties and
probable toxic effects of notified substances,
the BgVV has developed a computerized data-
base from data sets containing physicochemical
and toxicologic properties. The database has
been used to develop speciﬁc structure–activity
relationship (SAR) models for predicting skin
and eye irritation/corrosion, which have been
incorporated into a decision support system
(DSS) (Gerner et al. 2000a, 2000b; Zinke et al.
2000). Recently these and other data have been
used to verify skin irritation and corrosion
predictions (Hulzebos et al. 2003).
EU TGD for existing substance regulation
and notification of new substances. Existing
substance regulation. In 1993, the EU adopted
Council Regulation (EEC) 793/93, the
Existing Substance Regulation (EEC 1993b),
thereby introducing a comprehensive frame-
work for the evaluation and control of “exist-
ing” chemical substances. The regulation
was intended to complement the already exist-
ing rules governed by Council Directive
67/548/EEC (EEC 1967) for “new” chemical
substances. An “existing” chemical substance in
the EU is defined as any chemical substance
listed in the European Inventory of Existing
Commercial Substances (http://www.ecb.jrc.it/
existing-chemicals), which contains about
100,195 substances manufactured/imported
between 1 January 1971 and 18 September
1981. Regulation 793/93 foresees that the eval-
uation and control of the risks posed by existing
chemicals will be carried out in four steps: data
collection, priority setting; risk assessment, and
risk reduction:
Step 1: Data collection. The regulation was
initially concerned, in phases I and II of the data
collection step, with the so-called high–produc-
tion-volume (HPV) chemicals: substances that
have been imported or produced in quantities
exceeding 1,000 metric tons per year and pro-
duced or imported between 23 March 1990 and
23 March 1994. In phase III of the data collec-
tion step, companies that produce or import
existing substances in quantities between 10 and
1,000 metric tons per year (low–production-vol-
ume substances) were required to submit a
reduced data set by 4 June 1998. All the data
had to be submitted in a speciﬁc electronic for-
mat, the Harmonised Electronic DataSET
(Heidorn et al. 2003), and is incorporated in the
International Uniform ChemicaL Database
(IUCLID) (Heidorn et al. 2003).
Step 2: Priority setting. In consultation with
the member states, the commission regularly
draws up lists of priority substances that
require immediate attention because of their
potential effects to man or the environment.
The commission and member states use the
information collection during step 1 as a basis
for selecting priority substances. Since 1994,
four such priority lists have been published.
Step 3: Risk assessment. Substances on prior-
ity lists must undergo an in-depth risk assess-
ment covering the risks posed by the priority
chemical to people (covering workers, con-
sumers, and people exposed via the environ-
ment) and to the environment (covering the
terrestrial, aquatic, and atmospheric ecosystems
and accumulation through the food chain).
This risk assessment follows the framework set
out in Commission Regulation (EC) 1488/94
(EEC 1994) and implemented in the detailed
TGD on Risk Assessment for New and
Existing Substances. The EU member states
act as rapporteurs in the drafting of the risk
assessment reports, and the EC mediate
meetings, which attempt to reach consensus on
the conclusions of the risk assessments.
Step 4: Risk reduction. One possible outcome
of the risk assessment performed in step 3 is that
the chemical is considered to be a “substance of
concern” and that “further risk reduction mea-
sures, beyond those already in place, are
required.” In such cases a risk reduction strategy
is developed and implemented by means of
appropriate legal instruments such as Directive
76/769/EEC (EEC 1976a) on the restrictions in
marketing and use of dangerous substances.
Notification of new substances. New
chemicals, which have been notiﬁed before 18
September 1981, form a cumulative index called
the European List of New Chemical Substances
(http://www.ecb.jrc.it/existing-chemicals)
(ELINCS), which is periodically updated in the
Ofﬁcial Journal of the European Communities.
A harmonized European system for the
notiﬁcation of new substances was part of the
6th amendment to Directive 67/548/EEC
(Directive 79/831/EEC) (EEC 1976b), which
was concerned with the classiﬁcation, packag-
ing, and labeling of dangerous substances.
The 6th amendment was adopted in
September 1979 and came into force in all
member states on 18 September 1981 (EEC
1976b). A 7th amendment to Directive
67/548/EEC (Directive 92/32/EEC) (EEC
1992) was adopted in April 1992 and took
effect from November 1993 and introduced a
risk assessment for new notified substances.
Approximately 5,000 notifications in total,
representing about 3,000 substances, have
been submitted since 1981.
In the notification process, a technical
dossier on a new substance provides details of
the notiﬁer/manufacturer and the identity of
the chemical [International Union of Pure and
Applied Chemistry (IUPAC) name, CAS
number, etc.] and should provide information
on the substance such as its production process
and proposed uses, as well as physicochemical,
toxicologic, and ecotoxicologic data. Proposals
for classiﬁcation and labeling are also submit-
ted, including recommended precautions relat-
ing to safety. The amount of data required
increases according to the importation/produc-
tion volume of the chemical.
Toxic Substances Control Act Interagency
Testing Committee. The Interagency Testing
Committee (ITC) is not a regulatory organiza-
tion per se; however, there are 16 U.S. govern-
ment organizations represented on ITC, many
of which have regulatory responsibilities. The
ITC was created under section 4(e) of the
Toxic Substances Control Act (TSCA;
http://www.epa.gov/opptintr/iur/) as an inde-
pendent advisory committee to the U.S.
Environmental Protection Agency (U.S. EPA)
EPA Administrator (U.S. EPA 2002c). The
ITC was created to identify chemicals in need
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testing list in May and November reports to the
U.S. EPA Administrator (Walker 1993a). The
ITC has a statutory mandate under TSCA sec-
tion 4(e) to consider SARs when recommend-
ing chemicals for testing (Walker 2003). Several
U.S. government organizations represented on
the ITC have applied SARs, and those that
have applied QSARs include the U.S. EPA, the
U.S. Agency for Toxic Substances and Disease
Registry (ATSDR), and the U.S. Food and
Drug Administration (U.S. FDA) (Walker
2003). The QSAR applications of U.S. govern-
ment organizations have been previously
described (Walker 2003; Walker et al. 2002).
The health-effects–related QSAR applications
of the U.S. EPA, ATSDR, and U.S. FDA are
brieﬂy summarized below.
U.S. EPA. Section 5 of TSCA provides for
the regulation of new industrial chemicals by
the U.S. EPA. The U.S. EPA has received
about 38,000 premanufacture notifications
(PMNs) for new chemicals and currently
receives about 2,000 PMNs per annum.
Because the TSCA does not require testing
before submission of a PMN, few data are sub-
mitted and SARs and QSARs are used to pre-
dict health effects (Walker 2003).
ATSDR. In 1998, the ATSDR established
a computational toxicology laboratory and ini-
tiated efforts to use physiologically based phar-
macokinetic models, benchmark dose models,
and QSARs (El-Masri et al. 2002). The
ATSDR uses two commercial computational
toxicology models to make toxicity predictions
based on QSARs. The ATSDR used one of
these models to predict the toxicity of 15
chemicals from a hazardous waste site. The
model predicted that 9 of the 15 chemicals
have carcinogenicity potential, 6 have develop-
mental toxicity potential, and 6 have muta-
genicity potential (Walker 2003).
U.S. FDA. The U.S. FDA Center for Drug
Evaluation and Research (CDER) recently con-
sidered applications of QSARs to support regu-
latory decisions when toxicology data are
unavailable or limited (Matthews and Contrera
1998; Matthews et al. 2000). CDER evaluated
the ability of several QSAR-based commercial
computational toxicology models to make car-
cinogenicity predictions for about 400 pharma-
ceuticals that had been tested in 2-year
carcinogenicity studies (Matthews and Contrera
In press). As a result of these evaluations,
CDER is designing its computational toxicol-
ogy models to provide reliable toxicologic esti-
mates for FDA endpoints, coverage of U.S.
FDA-regulated drugs, and opportunities to pre-
dict effects of drugs in humans (Walker 2003).
To initiate the regulatory applications of
QSARs for drugs, CDER is developing an elec-
tronic toxicology database. The ﬁrst database to
be developed was the CDER rodent car-
cinogenicity database (Contrera et al. 1995a,
1995b). Acute, chronic, reproductive, and
developmental toxicity and genotoxicity data-
bases are being developed. Additional details are
available (U.S. FDA 2002).
Canadian regulatory agencies. Health
Canada is currently considering using QSARs
and expert systems to provide health effects pre-
dictions for the Canadian Domestic Substances
List (http://www.ccohs.ca/products/databases/
dsl.html), as Environment Canada has done for
ecologic effects and environmental fate predic-
tions (MacDonald et al. 2002).
Other organizations involved in the use of
SARs/QSARs. Despite not being formal regula-
tory agencies, two bodies, the European Centre
for Validation of Alternative Methods
(ECVAM) in the EU and the Interagency
Coordinating Committee on the Validation of
Alternative Methods (ICCVAM) in the
United States, have responsibility for the vali-
dation of alternative methods to the use of ani-
mals in the safety evaluation of chemical
substances. Alternative methods include in
vitro tests as well as QSARs and other com-
puter modeling techniques. ECVAM has eval-
uated the development and validation of expert
systems, including those using QSARs for pre-
dicting toxicity (Dearden et al. 1997). Other
organizations, such as the Fund for the
Replacement of Animals in Medical
Experimentation (FRAME; Nottingham,
England), have also been involved in the assess-
ment of alternative methods.
Another important organization that is
involved in the assessment of alternative
methods is the OECD. The OECD was
responsible for collating the results from a tri-
partite (United States, EU, Japan) assessment
of SARs to predict toxicity (Karcher et al.
1995; OECD 1994). This study considered
the predictions made by the EC and U.S.
EPA from respective minimum premarket
data (MPD). Of the health effects considered,
comparisons were made for the predictions of
metabolism, skin and eye irritation, skin sen-
sitization, systemic toxicity, mutagenicity, car-
cinogenicity, and several other endpoints.
The results of the study were useful in judg-
ing many of the strengths and weaknesses of
the U.S. approach, as well as in determining
the utility of MPD-type data in improving
U.S. assessment capabilities. The SAR/MPD
exercise confirmed that although the SAR
approach to screening the toxicity of new
chemicals is extremely useful in identifying the
ones that may be toxic, it is of limited value in
predicting the exact level and type of toxicity.
It was also noted that the set of chemicals
reviewed was not wholly representative of
chemicals reviewed for regulatory purposes.
With that in mind the exercise may have been
a worst-case analysis of the ability of the SARs
to predict which chemicals may present an
“unreasonable risk to human health (or the
environment)” [for more details on this com-
parative study, refer to U.S. EPA (2002d)].
Expert Systems to Predict
Toxicity
There are a number of software packages for
the prediction of human health effects and
related toxicities. These are described by the
general term “expert systems” (Dearden et al.
1997). Such systems allow toxicity to be pre-
dicted directly from chemical structure and
have been used by regulatory agencies and
industry alike because of their ease of use and
rapid application. Many may also be run in
batch mode to allow screening of large numbers
of compounds. Although expert systems for
toxicity prediction provide a convenient means
of predicting human health effects, little is cur-
rently known regarding their suitability or their
relevance of or accuracy for toxicity prediction
for many type of chemicals. Commonly used
commercial expert systems that are capable of
the prediction of a number of human health
endpoints are introduced in this section.
Specific modules, models, or rule bases are
described in relation to the relevant endpoint.
Further, their applications are described in
greater detail in following sections addressing
individual endpoints. These commercial pack-
ages have been evaluated and used, both for-
mally and informally, by a number of agencies,
including the Danish EPA, U.S. EPA, U.S.
FDA, and the U.K. Health and Safety
Executive (U.K. HSE). Details of the organiza-
tions using these programs are noted below and
are also available from Walker et al. (2002) and
OECD (2002b).
TOPKAT
TOPKAT is a statistically based system that
consists of a suite of QSAR models. It is mar-
keted by Accelrys Inc. [for more details, see
Accelrys Inc. (2002)]. Models are normally
derived after the analysis of large data sets of
toxicologic information, usually retrieved from
the literature. Molecules are characterized by
any of a large number of structural, topologic,
and electrotopologic indices. Models are devel-
oped using regression analysis for continuous
endpoints, and discriminant analysis for
categorizing toxicity data.
Computer-Automated Structure
Evaluation (CASE) Methodology
CASE methodology and all its variants were
developed by Klopman and colleagues
(Klopman 1992; Klopman and Rosenkranz
1991). There are a multitude of models for a
variety of endpoints and hardware platforms
[for more details, see MultiCASE Inc. (2002)].
The CASE approach uses a probability assess-
ment to determine whether structural frag-
ments are associated with toxicity. To achieve
this, molecules are split into structural
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Probability assessments determine whether the
fragments signiﬁcantly promote or inhibit toxi-
city. To create models, structural fragments are
incorporated into a regression analysis. There
are many forms of the CASE models; the soft-
ware is variously called CASE, MultiCASE
(MCASE), CASETOX, and TOXALERT
depending on the endpoint being modeled, the
hardware platform, and the endpoint.
Deductive Estimation of Risk from
Existing Knowledge (DEREK) for
Windows
DEREK for Windows is a knowledge base
expert system for the prediction of toxicologic
hazard (LHASA Ltd., Leeds, England). It uses
a knowledge base that contains alerts describ-
ing structure–toxicity relationships, with an
emphasis on the understanding of mechanisms
of toxicity and metabolism (http://www.chem.
leeds.ac.uk/luk/index.html). At the time of our
writing this article, there are a total of 296
alerts covering a wide range of toxicologic end-
points. An alert consists of a toxacophore (sub-
structure known or thought to be responsible
for the toxicity of a number of chemicals)
alongside associated literature references, com-
ments, and examples.
DEREK for Windows also contains an
argumentation model. This allows the program
to associate levels of likelihood with predictions
and gives it the ability to reason about the effects
of the physicochemical and known toxicologic
properties of a chemical. It is also able to extrap-
olate a prediction for one toxicologic endpoint
to a second related endpoint, to take advantage
of general toxicologic principles to ﬁll gaps in
available data. Therefore, it may be considered
that because DEREK for Windows predictions
no longer rely solely on the presence of alerts,
conﬁdence in the predicted absence of toxico-
logic activity may also be expressed in some
cases (Marchant CA. Personal communication).
Two regulatory agencies have purchased a
license for the DEREK for Windows system.
These are the U.S. HSE and the Agence
Française de Sécurité Sanitaire des Aliments in
France. Currently, DEREK for Windows is
used by the U.K. HSE only for internal and
informal use and is not used to support any
regulatory decisions.
HazardExpert
HazardExpert is a rule-based system using
known toxic fragments collected from in vivo
experimentation (Compudrug, Budapest,
Hungary). The knowledge base was developed
based on the list of toxic fragments reported by
more than 20 experts. In addition to toxicity,
HazardExpert also estimates toxicokinetic effects
such as bioaccumulation and bioavailability on
the basis of predicted physicochemical values. A
further application is its integration with the
MetabolExpert expert system (Compudrug,
Budapest, Hungary) to enable it to predict
the toxicity of both the parent compound and
the metabolites.
Optimized Approach Based on
Structural Indices Set (OASIS)
OASIS Forecast software was developed by
Mekenyan et al. (1990, 1994). The OASIS
Forecast is a shell system for screening chemical
inventories for physicochemical and toxic end-
points accounting for conformational ﬂexibil-
ity of chemicals. The software was designed for
personal computers with Microsoft Windows
and is an interfacing program providing
screening of chemicals by making use of QSAR
models. Models related to predicting biological
activities related to health effects are available
for estrogen and androgen binding afﬁnity and
mutagenicity. A metabolism model is also
being developed. Additional information on
OASIS is provided in the companion article in
this mini-monograph (Cronin et al. 2003) and
via the Internet (Laboratory of Mathematical
Chemistry 2002).
Substructure-Based Computerized
Chemical Selection Expert System
(SuCCSES)
SuCCSES was developed to facilitate the ITC
review of large groups of chemicals with similar
substructures (and modes of action, if avail-
able). SuCCSES and the substructures used to
facilitate the ITC review of large groups of
chemicals have been described previously
(Walker and Brink 1989; Walker 1991, 1995).
SuCCSES is used to facilitate the ITC’s review
of chemicals with similar substructures, not to
develop QSARs.
SuCCSES was developed based on histori-
cal information and expert opinions. Historical
information was obtained from the ITC’s scor-
ing exercises 1, 2, 3, 4, and 5 that were con-
vened from 1978 to 1983 (Walker 1993a,
1993b, 1995). For health effects, numerous
international experts were sent a questionnaire
listing more than 100 different chemical sub-
structures and were asked to predict (based on
their ﬁeld of expertise related to human health
effects and knowledge of modes or mecha-
nisms of action) the potential for chemicals
containing any of the substructures to cause
acute, chronic, mutagenic, carcinogenic, devel-
opmental, reproductive, or neurotoxic effects
or membrane irritation. Opinions from these
health effects experts were converted to codes
that identiﬁed chemical substructures and indi-
cated potential of chemicals containing one or
more substructures to cause specific health
effects. Additional information on SuCCSES is
provided in the companion article in this mini-
monograph (Cronin et al. 2003). Details have
been published previously (Walker and Brink
1989; Walker 1991, 1995).
The substructures in SuCCSES that were
associated with membrane irritation were
included in a recent publication (Hulzebos
et al. 2003). A forthcoming book chapter
(Walker and Gray. In press) summarizes the
development of SuCCSES and its applicability
to the ITC’s statutory mandate to use SARs
before recommending chemicals for testing in
May and November reports to the U.S. EPA
Administrator. SuCCSES is not available to
the public because it contains confidential
business information.
Prediction of Acute and Chronic
Toxicity
Some of the expert systems developed to
predict acute and chronic toxicity are described
below.
TOPKAT Model Rat Oral LD50
The Rat Oral LD50 module of the TOPKAT
package comprises 19 QSAR models and the
data from which these models are derived:
experimental acute median lethal dose (LD50)
values of approximately 4,000 chemicals from
the open literature. Each quantitative struc-
ture–toxicity relationship (QSTR) model
assesses oral LD50 for the rat for a speciﬁc class
of chemicals.
TOPKAT Model for Rat Chronic
Lowest Observed Adverse Effect Level
The Rat Chronic Lowest Observed Adverse
Effect Level (LOAEL) module of the TOP-
KAT package comprises five QSAR models
and the data from which the models are
derived. These models were developed from
393 uniform experimental LOAEL values
selected after critical review of the open litera-
ture, U.S. National Toxicology Program (U.S.
NTP) technical reports, and the U.S. EPA
databases.
TOPKAT Model for Rat Inhalation
Toxicity LC50
The Rat Inhalation Toxicity LC50 module of
the TOPKAT package comprises ﬁve QSAR
models and data from which these models
were derived. These multiple regression models
were derived from experimental median lethal
concentration (LC50) values on more than 643
chemicals after review of the open literature.
Reviewed literature data ranged over various
time limits; only exposure times in the range of
0.5–14 hr were accepted. Endpoints were
modeled as log10(1/C) – log10(hours of expo-
sure), where C is the concentration in
moles/m3. The chemicals are grouped into ﬁve
class-specific models: single benzenes, het-
eroaromatics and multiple benzenes, alicyclics,
and acyclics with and without halogens. Each
QSTR model assesses acute LC50 to rat of a
speciﬁc class of chemicals in units of moles per
cubic meter per hour.
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Tolerated Dose
The Rat Maximum Tolerated Dose module of
the TOPKAT package comprises three QSAR
models, and data from which these models are
derived; 256 uniform experimental data from
the U.S. NTP carcinogenesis reports are
grouped into three class-speciﬁc models: single
benzene, heteroaromatics and multiple ben-
zenes, and aliphatics. Two dosing regimens are
commonly used—either gavage or addition of
compound to water—both of which were con-
sidered in the modeling process. To reﬂect this
difference, two models are available to the user
and selectable from the menu, depending upon
the method of dosing. Endpoints have been
modeled as log10 (1/C), where C is the molar
concentration of dosed compound.
Regulatory Use
Danish EPA. The Danish EPA has reported
the use of the TOPKAT mouse LD50 model to
predict toxicity for compounds for which
experimental data were not available (Danish
EPA 2001).
The BgVV. The BgVV has developed a
database from regulatory test results that has
been used to develop speciﬁc SAR models to
predict local skin and eye irritation and corro-
sion (EU classiﬁcations R34, R35, R36, R38,
and R41) (Commission of the European
Communities 2001). These models have been
incorporated into a DSS (Gerner et al. 2000a,
2000b; Zinke et al. 2000). The DSS is mainly a
rule-based approach, with rules developed based
on not only substructural molecular features but
also on physicochemical properties such as mol-
ecular weight, aqueous solubility, and logarithm
of the octanol–water partition coefﬁcient (log
Kow). The rules have been developed and vali-
dated on a total of 1,562 compounds (of which
385 are classiﬁed as hazardous) for oral toxicity,
1,043 compounds (44 hazardous) for dermal
toxicity, and 154 compounds (35 hazardous) for
inhalation toxicity. The DSS is designed to pre-
dict EU risk phrases such as R34, R35, etc.
Prediction of Mutagenicity
Mutagenicity is an important human health
endpoint. It represents a genotoxic event. A
considerable number of chemicals have been
tested for mutagenicity, and these have formed
the basis of a number of QSAR analyses and
expert systems. Mutagenicity data may be used
in two manners for modeling. First, and most
commonly in expert systems, they may be used
in a quantitative manner to predict the possi-
bility of a mutagenic event. Second, and more
commonly in individual QSAR analyses, rela-
tive potency may be quantiﬁed and predicted.
QSARs
As with other endpoints, QSARs have been
developed for classes of chemicals. These tend
to provide good relationships of potency
because for some classes such as the aromatic
amines (Hatch et al. 2001), all compounds can
be considered to be acting by the same, or very
similar mechanism of action. Other more gen-
eral models have been developed, for instance,
for aromatic compounds with a nitro func-
tional group. For these models, statistical fit
tends to be poorer, and the mechanisms more
diverse. As with all models on chemical classes,
these QSARs cannot be applied outside the
chemical class on which they have been trained
and so are of only limited value for regulatory
application unless they can be formalized into
some hierarchical framework to allow chemi-
cals to be assigned to classes. QSARs for pre-
dicting mutagenicity have been reviewed
recently [Patlewicz et al. In press (a)].
Expert Systems
HazardExpert. HazardExpert contains a num-
ber of rules for the prediction of mutagenicity.
DEREK for Windows. DEREK for
Windows contains 76 structural alerts for
mutagenicity.
TOPKAT. The Ames mutagenicity mod-
ule of the TOPKAT package is composed of
10 QSAR models and the data from which
these models are derived. Each model applies
to a speciﬁc class of chemicals. These QSARs
are linear discriminant analysis models based
on positive and negative categories. The model
is derived from 1,866 uniform studies selected
after critical review of open-literature histidine
reversion assays using Salmonella typhimurium
strains. The QSARs compute the probability
of a submitted chemical structure being a
mutagen in the histidine reversion assay; a
probability below 0.3 indicates a nonmutagen,
and a probability above 0.7 signiﬁes a muta-
gen. The probability range between 0.3 and
0.7 refers to the “indeterminate” zone.
CASE. The CASE algorithm has been
trained on a number of mutagenicity data-
bases. These models provide an estimate of the
likelihood of the toxicologic events occurring.
Included in the models are the NTP Sister
Chromatid Exchange (233 compounds), NTP
Chromosomal Aberration Assay (233 com-
pounds), Micronuclei Induction (236 com-
pounds), Cell Transformation—Balb/C 3T3
(183 compounds) (which may also include
information on nongenotoxic mechanisms),
Unscheduled DNA Synthesis Induction (299
compounds), SOS Chromotest (462 com-
pounds), NTP Salmonella (1354 compounds),
GeneTox (573 compounds), Drosophila
Mutation (289 compounds), and the Ashby
Structural Alerts (784 compounds) (http://
www.toxnet.nlm.nih.gov).
OASIS. The OASIS forecast software
includes a suite of modules. One of these mod-
ules, Common Reactivity Pattern (COREPA),
is a pattern-recognition method for identifying
common stereoelectronic (reactivity) patterns of
structurally diverse chemicals that exert similar
biological effects. The COREPA approach is
not dependent upon predetermined toxi-
cophores or alignment of conformers to a lead
compound. COREPA was used to identify
structural requirements for eliciting mutagenic
effects (Mekenyan OG. Personal communica-
tion). Elucidation of this pattern required
examination of the conformational ﬂexibility of
the compounds, revealing areas in the multidi-
mensional descriptor space that were most pop-
ulated by the conformers of mutagenic
chemicals and least populated by nonmutagenic
ones (including chemicals that become muta-
genic after metabolic activation). The QSAR
analysis was based on Salmonella data from the
U.S. NTP (http://www.toxnet.nlm.nih.gov).
The training set was conﬁned to a single strain,
TA100, because of the complexity of the data.
The mutagenicity profile was described as a
hierarchically ordered set of rules based on
ranges of parameter variations. The structural
factors controlling the effect were global reactiv-
ity of chemicals [Egap =  E(HOMO) –
E(LUMO)] combined with their ability to take
part in SE2 (local electronic charges) and SE1
(reactive fragments) electrophilic reactions.
These signiﬁcant factors were tuned by addi-
tional structural requirements associated with
molecular polarity and surface. Based on
derived reactivity patterns, a descriptor proﬁle
(decision tree) was established for identifying
mutagenic chemicals. The model correctly
identiﬁed 137 of 148 (93%) of the direct acting
mutagens in the training set, and 789 of 820
(96%) of the nonmutagens in the training set.
A system that identifies those chemicals that
require metabolic activation has also been
developed. This model correctly identiﬁed 201
of 229 (88%) of the chemicals in a training set
(Mekenyan OG. Personal communication).
Regulatory Use
Danish EPA. The Danish EPA applied a tiered
selection of models for the prediction of muta-
genicity. The models used include the MCASE
Model A2E (Ashby and Tennant 1991; struc-
tural alerts for DNA reactivity), model A62
(induction of micronuclei), model A2H
[Salmonella (Ames) mutagenicity], model A61
(chromosomal aberrations), and model A2F
(mutations in mouse lymphoma) as well as
TOPKAT Salmonella (Ames) mutagenicity
model. The predictions from these models were
integrated to allow systematic evaluation, along
with expert evaluation, for the prediction of the
EU mutagenic classiﬁcation R40 (Commission
of the European Communities 2001).
Prediction of Carcinogenicity
Carcinogenicity still remains one of the most
difficult toxicologic endpoints to assess and
comprehend experimentally. Because of the
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mental measurement, the prediction of this
endpoint is very attractive. A large number of
systems and models dedicated to the prediction
of carcinogenicity have been developed
(Richard 1998). The prediction of carcino-
genicity has also beneﬁted from two blind trials
organized by the U.S. NTP. These have
demonstrated that carcinogenicity is generally
only poorly predicted, and the best models tend
to be those that can integrate mechanism-based
reasoning with biological data (Richard and
Benigni 2002).
QSARs
QSARs for carcinogenicity were reviewed by
Cronin and Dearden (1995a) and Patlewicz
et al. [In press (a)]. A relatively small number
of QSARs exist for distinct chemical classes. In
such examples the assumption is made that
structurally similar chemicals may act by simi-
lar mechanisms of action. Good examples are
provided by Franke et al. (2001), who demon-
strated both the modeling of activity (carcino-
genic vs. noncarcinogenic) and the potency of
aromatic amines (from the carcinogenicity
potency database). As with all class-based
QSARs, their use is restricted by the domain of
the QSAR.
Expert Systems
A large number of expert systems exist for
prediction of carcinogenicity. Some systems
and approaches are solely dedicated to the pre-
diction of carcinogenicity; others are part of
systems that cover a greater number of toxico-
logic endpoints. Some good reviews exist on
the possibilities for predicting carcinogenicity
(Richard 1998; Richard and Benigni 2002;
Hulzebos et al. 1999).
DEREK for Windows. At the time of our
writing this article, DEREK for Windows con-
tained 46 alerts for the prediction of carcino-
genicity. Further, the argumentation model in
DEREK for the Windows system allows pre-
dictions of carcinogenicity in appropriate
species to be extrapolated from predictions for
endpoints known to be related to carcinogenic-
ity, such as peroxisome proliferation.
HazardExpert. At the time of writing
HazardExpert contained a number of rules for
the prediction of carcinogenicity.
OncoLogic. OncoLogic (LogiChem Inc.,
Boyertown, PA, USA) is an expert system that
assesses the potential of chemicals to cause can-
cer. It is marketed by LogiChem Inc. which,
established in 1986, is owned and operated by
a group of biochemical and computer science
professionals. OncoLogic predicts the potential
carcinogenicity of chemicals by applying the
rules of SAR analysis and incorporating what is
known about mechanisms of action and
human epidemiologic studies. OncoLogic was
developed in cooperation with the U.S. EPA
Structure Activity Team involved in the PMN
process. OncoLogic has the ability to reveal its
line of reasoning, just as human experts can.
After supplying the appropriate information
about the structure of the compound, an
assessment of the potential carcinogenicity and
the scientiﬁc line of reasoning used to arrive at
the assessment outcome are produced. This
information provides a detailed justiﬁcation of
a chemical’s cancer-causing potential.
OncoLogic can evaluate the following classes
of compounds: ﬁbers, polymers, metals, metal-
loids, and metal-containing compounds as well
as organic chemicals.
TOPKAT. The TOPKAT software
comprises a number of modules for the predic-
tion of carcinogenicity. Each is described in
more detail below.
The U.S. FDA Rodent Carcinogenicity
module of the TOPKAT package is composed
of eight QSTR models and the data from which
these models are derived. Each QSTR model
relates to a speciﬁc sex/species combination—
male rat, female rat, male mouse, and female
mouse—each of which is further divided into
carcinogen versus noncarcinogen and multiple-
versus single-site models. These discriminant
models, derived from data provided by the U.S.
FDA CDER under a material transfer agree-
ment, compute the probability of a submitted
chemical structure being a carcinogen. In the
ﬁrst-stage model, carcinogen versus noncarcino-
gen, a computed probability below 0.3 indicates
a noncarcinogen, and probability above 0.7 sig-
niﬁes a carcinogen. The second-stage model,
multiple versus single site, can then be applied
to carcinogens. The probability range between
0.3 and 0.7 refers to the “indeterminate” zone.
The NTP Rodent Carcinogenicity Module
of the TOPKAT package comprises four QSTR
models and the data from which these models
are derived. Each QSTR model relates to a spe-
ciﬁc sex/species combination: male rat, female
rat, male mouse, and female mouse. These dis-
criminant models, derived from uniform studies
selected after critical review of technical reports
on 366 rodent carcinogenicity tests conducted
by the National Cancer Institute (NCI) and the
U.S. NTP using inbred rats and hybrid mice,
compute the probability of a submitted
chemical structure being a carcinogen.
The Weight-of-Evidence Rodent
Carcinogenicity Module of the TOPKAT
package comprises a single QSTR model and
the data from which this model is derived. The
QSTR model scores the chemical using the
U.S. FDA CDER weight-of-evidence protocol,
which scores the chemical as a carcinogen if a)
it is a multiple-site carcinogen in at least one
sex/species combination (male or female/rat or
mouse) or b) it is a single-site carcinogen in at
least two sex/species combinations. This dis-
criminant model, derived from data provided
by the CDER and from uniform studies
selected after critical review of technical reports
on rodent carcinogenicity studies conducted by
the NCI and the U.S. NTP, computes the
probability of a submitted chemical structure
being a carcinogen.
CASE. There are a number of modules for
the prediction of carcinogenicity available in
the MCASE software. These include the NTP
Rodent assay (model developed on 313 com-
pounds), NTP Mouse (319 compounds),
NTP Rat (316 compounds), Gold CPDB
Rodent (433 compounds), Gold CPDB Rat
(636 compounds), Gold CPDB Mouse (745
compounds), NTP Female Rat (314 com-
pounds), NTP Male Rat (286 compounds),
NTP Female Mouse (286 compounds), and
the NTP Male Mouse (274 compounds)
(http://www.toxnet.nlm.nih.gov).
Other less formalized models. RASH. The
rapid screening of hazards (RASH) method pre-
dicts carcinogenic potential based on the
observed relative potencies of tested chemicals in
different short-term bioassays. It is not fully
automatic and requires a human expert to select
relevant comparisons (Jones and Easterly 1996).
Purdy’s model. Purdy (1996) reported a
hierarchical model consisting of QSARs based
mainly on chemical reactivity that was devel-
oped to predict the carcinogenicity of organic
chemicals to rodents. The model is composed
of QSARs based on hypothesized mechanisms
of action, metabolism, and partitioning. A
large number of physicochemical predictors
were used to individually model different
mechanisms of action. The model correctly
classiﬁed 96% of the carcinogens in the train-
ing set of 306 chemicals and 90% of the
carcinogens in the test set of 301 chemicals.
Regulatory Use
Danish EPA. Predictions of potential
carcinogenicity were made after a number of
QSAR approaches. An initial assessment of the
compounds was made by the prediction of
mutagenicity (as described above). The focus
of the prediction acknowledged that although
many compounds could promote carcino-
genicity via a nongenotoxic mechanism, the
screening would identify only those com-
pounds associated with genotoxicity.
Subsequent to the prediction of genotoxicity,
the TOPKAT NTP and U.S. FDA models for
carcinogenicity (all species and sexes) were
applied. In addition two MCASE models
based on the carcinogenicity potency database
were also used.
U.S. FDA. The U.S. FDA has been
instrumental in the release of data and infor-
mation from regulatory submissions. Matthews
and Contrera (1998) report the development
of MULTICASE for the prediction of carcino-
genicity using data released from the U.S. FDA
under a cooperative research and development
agreement (CRADA). The model developed
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predictivity.
Other reports from the U.S. FDA report
the use of TOPKAT to make predictions of
the carcinogenicity of pharmaceutical sub-
stances. The results of a trial using TOPKAT
to predict the carcinogenicity of chemicals
tested by the U.S. NTP were disappointing,
with a low rate of successful prediction (Prival
2001). It should be emphasized that the results
of this trial should not be taken in isolation.
The performance of TOPKAT is unlikely to
be signiﬁcantly different from other expert sys-
tems. This trial simply conﬁrmed the difﬁculty
in predicting this endpoint and that computa-
tional prediction of carcinogenicity is complex.
U.S. EPA. The U.S. EPA Office of
Pollution Prevention and Toxics (OPPT) reg-
ularly uses the SARs contained within the
OncoLogic system to assess the carcinogenic
potential of substances (Woo et al. 1995).
NCI. The NCI’s use of SARs is illustrated
by the review of juglone (CAS Registry No.
481-39-0), a potentially toxic natural product,
reported in Walker (2003). The NCI
Chemical Selection Working Group reviewed
three structurally related chemicals and associ-
ated genotoxicity data and concluded that
juglone should be recommended for carcino-
genicity testing to the U.S. NTP.
Reproductive Toxicity/
Developmental Toxicity
Along with carcinogenicity, the experimental
assessment of reproductive toxicity and devel-
opmental toxicity is one of the most costly,
time-consuming, and mechanistically complex
endpoints to perform.
QSARs
Cronin and Dearden (1995b) reviewed
QSARs for the prediction of reproductive toxi-
city. Because of the paucity of published data,
there are relatively few published QSARs.
Typically, many of the more successful
approaches to predicting developmental toxic-
ity, in particular, have resulted from the analy-
sis of distinct chemical classes.
Expert Systems
DEREK for Windows. DEREK for Windows
has a small number of alerts for reproductive
toxicity, developmental toxicity, and terato-
genic effects.
HazardExpert. HazardExpert has a number
of rules for teratogenic effects.
TOPKAT. The Developmental Toxicity
Potential Module of the TOPKAT package
comprises three QSAR models and the data
from which these models are derived. Each
model applies to a speciﬁc class of chemicals.
These discriminant models, derived from
uniform experimental studies selected after
critical review of approximately 3,000 open
literature citations, compute the probability of
a submitted chemical structure being a devel-
opmental toxicant in the rat; a probability
below 0.3 indicates no potential for develop-
mental toxicity, and probability above 0.7 sig-
nifies developmental toxicity potential. The
probability range between 0.3 and 0.7 refers to
the “indeterminate” zone.
CASE. The CASE software comprises a
number of models for the prediction of devel-
opmental toxicity. These include a model for
triazoles (based on 66 compounds), a compos-
ite model (275 compounds), developmental
toxicants for mouse (101 compounds), devel-
opmental toxicants for rat (134 compounds),
developmental toxicants for rabbit (66 com-
pounds), developmental toxicants for humans
(119 compounds), and FDA + TERIS (http://
www.depts.washington.edu/~terisweb/teris)
data sets (323 compounds).
Prediction of Eye Irritation
Eye irritation is a complex and emotive
toxicologic endpoint to assess experimentally.
Regulatory classiﬁcations of ocular toxicity are
made from the assessment of several different
endpoints. Because the toxic effect may be
elicited by either physical (corrosive) or biolog-
ical effects, efforts to predict eye irritation have
often been inadequate.
QSARs
A large number of approaches to predict eye
irritation using QSARs have been applied.
These have been reviewed recently by Cronin et
al. (In press) and Patlewicz et al. [In press (b)].
Many of the efforts have centered on the mod-
eling of eye irritation as a nonlinear event (e.g.,
Worth and Cronin 1999), membrane interac-
tion (Kulkarni et al. 2001), or more traditional
QSAR analyses (e.g., Abraham et al. 1998a,
1998b). Recently Worth (2000; Cronin et al.
In press) extended the OECD tiered assessment
regime to incorporate physical (pH) data, a
QSAR model, and in vitro data.
Expert Systems
DEREK for Windows. DEREK for Windows
contains a total of 33 alerts for irritation; 29 of
these include consideration of irritation of 
the eye.
HazardExpert. HazardExpert contains a
number of rules for irritation.
TOPKAT. The Ocular Irritancy module of
the TOPKAT package comprises 15 QSARs
and the data from which these models are
derived. Each model applies to a speciﬁc class of
chemicals, each of which is further subdivided
into three groups on the basis of severity. These
models, based on 1,453 uniform studies
selected after critical review of open literature,
compute the probability of a submitted
chemical structure being an ocular irritant in
the Draize eye irritation test. In the ﬁrst stage,
nonirritants and mild irritants combined are
classified in contrast to moderate and severe
irritants combined. At the second stage, nonir-
ritants are separated from mild irritants, and
moderate separated from severe irritants.
CASE. The MultiCASE software comprises
a model for eye irritation, developed from the
results of 207 Draize tests.
Regulatory Use
The BgVV. The BgVV has developed a database
from regulatory test results that has been used to
develop speciﬁc SAR models for predicting eye
irritation/corrosion, which have been incorpo-
rated into a DSS (Gerner et al. 2000a, 2000b;
Zinke et al. 2000). The DSS is mainly a rule-
based approach, the rules being developed on
not only substructural molecular features but
also on physicochemical properties such as mol-
ecular weight, aqueous solubility, and log Kow.
The rules have been developed and validated on
a total of 1,484 compounds (of which 405 are
classified as being hazardous). The DSS is
designed to predict EU risk phrases.
Skin Irritation/Corrosivity
The assessment of skin irritancy and corrosivity
is important for chemicals that may be der-
mally applied or for occupational exposure by
this route.
QSARs
There have been relatively few QSARs of skin
irritation or corrosivity, and these have been
reviewed recently by Cronin et al. (In press),
Hulzebos et al. (2003), and Patlewicz et al. [In
press (b)].
Expert Systems
DEREK for Windows. DEREK for Windows
contains a total of 33 alerts for irritation, 25 of
which include consideration of irritation of 
the skin.
HazardExpert. HazardExpert contains a
number of rules for irritation.
TOPKAT. The Rabbit Skin Irritation
Module of the TOPKAT comprises 13 QSAR
models, and data from which these models are
derived. Each model applies to a speciﬁc class
of chemicals, and each model is further subdi-
vided into two or three groups based on sever-
ity. Compounds and data were collected from
national and international journals as well as
U.S. government sources for a total of 1,258
compounds. The chemicals are grouped into
ﬁve class-speciﬁc models: heteroaromatics and
multiple benzenes, alicyclics, single benzenes,
and two classes of acyclics. Each class-speciﬁc
model in turn has severity-speciﬁc submodels.
Regulatory Use
The BgVV. The BgVV database has been used
to develop speciﬁc SAR models for predicting
skin irritation/corrosion. These models have
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2000a, 2000b; Zinke et al. 2000). As with the
discussion for eye irritation (above), the DSS is
mainly a rule-based approach, the rules being
developed based not only on substructural
molecular features but also on physicochemical
properties such as molecular weight, aqueous
solubility, and log Kow. The rules have been
developed and validated on a total of 1,508
compounds (of which 199 are classified as
being hazardous). The DSS is designed to
predict EU risk phrases.
Prediction of Skin Sensitization
Skin sensitization is another important
toxicologic endpoint for substances that may
come in contact with the skin. Essentially, skin
sensitization is an immunologic response, and
as such, there are no validated in vitro alterna-
tives to in vivo testing.
QSARs
Skin sensitization requires two fundamental
processes to proceed: the passage of a chemical
through the skin, and the interaction of the
chemical with a skin protein to trigger the
immunologic response. A number of QSAR
analyses have been performed. Basketter et al.
(1992) demonstrated that the potency of skin
sensitization for a series of haloalkanes was
related to their ability to cross the skin, and
their relative alkylating potential once at the
site of action. Other analyses have been more
multivariate in nature (Cronin and Basketter
1994; Magee et al. 1994). QSARs for skin sen-
sitization have been reviewed by Rodford et al.
(In press).
Expert Systems
DEREK for Windows. DEREK for Windows
contains a total of 59 alerts for skin sensitization
and ﬁve alerts for photoallergenicity. The pre-
dictive performance of these alerts has been
assessed by Barratt and Langowski (2000). In
addition, an argumentation model in the
DEREK for Windows system allows predictions
in these areas to take account also of the percu-
taneous absorption of the chemical of interest as
calculated from the Potts and Guy (1992) equa-
tion. Chemicals for which percutaneous absorp-
tion is calculated to be low are associated with a
reduced level of likelihood of activity (Marchant
CA. Personal communication).
HazardExpert. HazardExpert contains a
number of rules for all types of sensitization.
TOPKAT. The Skin Sensitization Module
of the TOPKAT package is a suite of two
modules, one for nonsensitizers versus sensitiz-
ers and the other for weak/moderate versus
strong sensitizers. Each module comprises two
QSARs models applicable to a speciﬁc class of
chemicals and the data from which these mod-
els were derived; 335 uniform studies selected
after critical review of guinea pig maximization
test assays in the open literature were used to
develop these models.
CASE. A CASE model for skin sensitization
has been developed for the human exposure of
1,034 chemicals.
Regulatory Use
Danish EPA. The Danish EPA used two
approaches to predict skin sensitization. The
ﬁrst was the use of the TOPKAT skin sensiti-
zation module. Compounds predicted to be
strong allergens were considered likely to ful-
fill the criteria for EU classification R43
(Commission of the European Communities
2001). Second, the MCASE allergic contact
dermatitis model was applied. Again, com-
pounds that were predicted to be very active
were considered to meet the criteria for
R43 classiﬁcation.
The BgVV. The BgVV has initiated a
process of validation and development of skin
sensitization alerts. These alerts have been
incorporated into a DSS (Gerner et al. 2000a,
2000b; Zinke et al. 2000). The performance of
the alerts has been assessed using a database of
1,039 chemicals (of which 403 are classiﬁed as
being skin sensitizers). Some weaknesses in the
alerts were identiﬁed (Zinke et al. 2002). The
DSS is designed to predict EU risk phrases.
Prediction of Percutaneous
Absorption
The assessment of the ability of a chemical to
cross the skin is important for risk assessment
of dermal toxicity but need not necessarily be
considered as a toxicity test per se. There are a
variety of in vitro and in vivo methodologies to
assess percutaneous absorption. Probably the
most widespread and potentially useful is the
use of excised human skin in vitro.
QSARs
QSARs for skin permeability are well reviewed
by Moss et al. (2002) and Walker et al. (2003).
The passage of chemicals across the skin may
be viewed as a passive diffusion process. As
such, most success from modeling skin perme-
ability has come from the use of descriptors for
hydrophobicity and molecular size. Also, a
number of issues regarding data quality from
historical sources have made modeling more
complex.
Expert Systems
Syracuse Research Corporation’s Dermwin
Program. This program estimates the dermal
permeability coefﬁcient (Kp) and the dermally
absorbed dose per event (DA event) of organic
compounds from their chemical structure and
Syracuse Research Corporation’s (Syracuse,
NY, USA) LogKow (KOWWIN) program to
estimate Kow. The estimation methodology was
taken from the U.S. EPA (1992). The program
uses one general estimation equation and three
class-specific estimation equations to predict
Kp. DA event is predicted by two separate
methods (an adapted equation of Fick’s first
law and another method, both of which are
indicated in the U.S. EPA report) and requires
a) input of the duration of the event and b)
concentration of the chemical in water (a
default water solubility using the method in
the Syracuse Research Corporation’s WsKow
program is calculated for the user if no value
is entered).
Random walk model. The random walk
model is new mathematical model for perme-
ability of chemicals in aqueous vehicle
through skin (Frasch 2002). The rationale for
this model is to represent diffusion by its fun-
damental molecular mechanism, that is, ran-
dom thermal motion. Diffusion is modeled as
a two-dimensional random walk through the
biphasic (lipid and corneocyte) stratum
corneum.
Regulatory Use
U.K. HSE. The U.K. HSE has funded two
studies into use and validation of a knowledge-
based system for the prediction of dermal
absorption, the system being based on SARs
(Dick and Williams 1998; Wilkinson and
Williams 2001). However, the HSE does not
make routine use of these findings, and the
ﬁndings do not reﬂect HSE policy.
ITC. Walker et al. (2003) described the
regulatory application of QSARs to predict
dermal absorption of compounds. The perme-
ability coefﬁcient was predicted by a series of
simple QSARs that were based either on
hydrophobicity and molecular size or on
hydrophobicity alone.
Use of (Q)SARs to Assess the
Human Health Effects of HPV
Chemicals
Under the U.S. EPA HPV Chemical Challenge
Program (Challenge Program) (Walker et al. In
press) the chemical industry is being challenged
to voluntarily compile a screening information
data set (SIDS) for chemicals on the U.S. HPV
list. The SIDS, which has been internationally
agreed to by member countries of the OECD,
provides basic screening data needed for an ini-
tial assessment of the physicochemical proper-
ties, environmental fate, and human and
environmental effects of chemicals. The infor-
mation used to complete the SIDS can come
either from existing data or from new tests con-
ducted as part of the Challenge Program. The
Challenge Program chemical list, available
online (U.S. EPA 2002b), consists of about
2,800 HPV chemicals reported under the
TSCA 1990 and 1994 Inventory Update Rule.
The large number of chemicals on the list
makes it important to reduce the number of
tests to be conducted, where this is scientiﬁcally
justiﬁable. SARs may be used to reduce testing
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a number of structurally similar chemicals as a
group, or category, and allowing selected mem-
bers of the group to be tested with the results
applying to all other category members; b) by
applying SAR principles to a single chemical
that is closely related to one or more better
characterized chemicals (analogues), the ana-
logue data are used to characterize the speciﬁc
endpoint value for the HPV candidate chemi-
cal; and c) a combination of the analogue and
category approaches may be used for individual
chemicals. For example, one could search for a
“nearest chemical class,” as opposed to a near-
est single chemical analogue, to estimate a
SIDS endpoint.
Guidance on the Use of SARs for the
Prediction of Human Health Effects 
of HPV Chemicals
The SIDS manual (OECD 2002a), with
guidance on the use of SAR in the OECD SIDS
program, consists mainly of citations to OECD
and other documents. There is no speciﬁc guid-
ance for the use of SAR in assessing mammalian
toxicity. The manual also lists some examples of
the potential use of SAR: groups of isomers with
similar SAR profiles; close homologues; and
availability of information on precursors, break-
down products, and metabolites/degradation
products of speciﬁc chemicals.
SARs for health effects (summarized in
Table 1) are different from the other SIDS
endpoints. This is because of the variety of sce-
narios (acute vs. chronic exposure conditions,
in vitro vs. in vivo tests) and endpoints (e.g.,
general toxicity, organ-speciﬁc effects, muta-
genicity, developmental effects, effects on fer-
tility). Therefore, generic QSAR models are
either not readily available or not widely
accepted [for a review, see Hulzebos et al.
(1999)], and an analogue approach is a reason-
able way to proceed.
Scope and Applications in the Use of
(Q)SARs in the U.S. HPV Challenge
Program
The use of SAR/QSAR in the U.S. HPV
Challenge Program is expected to decrease the
number of new tests required to develop a
SIDS for each HPV chemical. Their use, by
either the category or individual chemical
approach, will necessarily be limited by the
nature of the SIDS endpoint, the amount and
adequacy of the existing data, and the type of
SAR/QSAR analysis performed. Measured
data developed using acceptable methods are
preferred over estimated values. The develop-
ment and use of SAR/QSAR in the Challenge
Program will be different for each of the major
categories of SIDS (i.e., physicochemical prop-
erties, environmental fate, ecotoxicity, and
health effects). In the final analysis, because
the goal of the program is to adequately
characterize the hazard of HPVs, a careful,
reasonable, and transparent argument using
measured data and estimation techniques will
need to be presented.
The estimation of toxicity to mammals is
complicated because there are a variety of
endpoints (mutagenicity vs. general toxicity vs.
reproductive/developmental toxicity) and expo-
sure (in vitro vs. in vivo and acute vs. chronic)
conditions. In addition, the available SAR pro-
grams are very different from each other and
unique to certain endpoints, and most are not
validated [for a review, see Hulzebos et al.
(1999)]. Therefore, in all cases, SAR estimations
for a health endpoint must be accompanied by
experimental data with a close analogue.
Predictions for Individual Chemicals
For individual chemicals, SAR is applied in
two ways: a) by the use of (usually quantita-
tive) predictive models based on well-validated
data sets (QSAR) and b) by comparing the
chemical with one or more closely related
chemicals, or analogues, and using the ana-
logue data in place of testing the chemical. In
the case of models, the comparison has essen-
tially been incorporated into the model.
In developing a SAR, proposers (i.e.,
developers who propose a SAR) need to con-
sider the following steps for each HPV chemi-
cal they are interested in sponsoring:
• Step 1: Conduct literature search
• Step 2: Determine data adequacy by SIDS
endpoint
• Step 3: Identify data gaps by SIDS endpoint
• Step 4: Use SAR or perform test, by SIDS
endpoint
Health Endpoint Estimation Techniques
Hulzebos et al. (1999) reviewed the literature on
QSARs for human toxicologic endpoints and
divided the available estimation techniques into
three groups: rule-based systems (e.g.,
HazardExpert, DEREK for Windows), statisti-
cally based systems (TOPKAT, MULTICASE),
and systems that are a combination of the two
(RASH). Rule-based SARs rely on placing
chemicals into categories by presumed mecha-
nism of action, and statistical-based SARs use
statistically derived descriptors to predict the
activity of a chemical and thus may be applica-
ble to a more heterogeneous group of chemicals.
Hulzebos et al. (1999) noted that more val-
idation is needed to correlate SAR with individ-
ual health endpoints. For the purposes of the
U.S. HPV Challenge Program—to adequately
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Table 1. Use of SARs in the U.S. HPV Challenge Program: human health effects.
Approach SIDS endpoint Comment
Category All Assemble information on all endpoints for all category members to determine 
whether trends exist that would allow adequate characterization
Nearest analogue Health Depends upon existing data for analogue chemical to estimate the effect of 
the HPV candidate chemical
Table 2. SAR model used by the U.S. EPA for SIDS human health endpoints.
SIDS endpoint SAR model
Acute toxicity Nearest analogue analysis using expert judgment
General toxicity (repeated dose)
Genetic toxicity (effects on the gene and chromosome)
Reproductive/developmental toxicity
Table 3. Framework of QSARs for human health effects for regulatory purposes.a
Acute Dermal Subchronic Chronic Reproductive Developmental Immunological
Organization toxicity Irritation Sensitization absorption toxicity toxicity toxicity toxicity Mutagenicity Carcinogenicity toxicity Neurotoxicity
ATSDR QQ Q
U.S. EPA S S S S S Q S S S S S
U.S. FDA Q
ITC S S S S Q S Q S S S S S
NCI SS
U.S. NTP S S S S
NIOSH Q S
BgVV S S
Danish EPA Q Q Q Q
Abbreviations: NIOSH, U.S. National Institute of Occupational Safety and Health; Q, use of QSARs; S, use of SARs.
a Modiﬁed from Walker et al. (2002).characterize the hazard of an HPV—the
above-mentioned models could not replace an
actual test. However, there is an opportunity to
use SARs for health endpoints in the Challenge
Program. Given the complexity of health end-
points and the amount of uncertainty in many
models, OPPT has historically used an expert
judgment/nearest-analogue approach to SARs
for predicting such effects in assessing new
chemicals. OPPT suggests that a similar
approach be applied in the Challenge Program.
The goal is to ﬁnd toxicity data for an analogue
that can be used to address the testing needs of
an HPV chemical. This is best done on an end-
point-by-endpoint and case-by-case basis.
Valid analogues should have close
structural similarity and the same functional
groups. In addition, the following parameters
should be compared between the chemical and
its analogue(s): physicochemical properties—
physical state, molecular weight, log Kow, water
solubility; absorption potential; mechanism of
action of biological activity; and metabolic
pathways/kinetics of metabolism. A high corre-
lation between the HPV chemical and the
putative analogue for most of these parameters
improves the chance that a SAR approach will
be reasonable and acceptable. A more convinc-
ing argument can be made for the use of surro-
gate data if there are toxicity studies in
common (i.e., ones that are not necessarily
SIDS endpoints but have been done with both
the analogue and the HPV candidate chemical)
that demonstrate the toxicologic similarity of
the chemicals.
The following presents possible examples
of the use of surrogate data to characterize
individual chemicals:
• Chemicals that are essentially the same in
vivo: For example, different salts of the same
anion or cation. The salts must fully dissoci-
ate in vivo, and the counter ion must not
contribute any more (or less) toxicity.
• A chemical that metabolizes to one or more
compounds that have been tested: The
metabolism must be rapid and complete.
• Chemicals that have only minor structural
differences that are not expected to have an
impact on toxicity: All functional groups
must be the same.
Table 2 provides a summary of the SAR
models discussed above.
Conclusions
Main Findings
A framework of QSARs has been established by
regulatory agencies worldwide (Table 3). By far
the greatest use and application of QSARs have
resulted from the TSCA and the efforts of the
U.S. EPA and U.S. FDA. The regulatory use of
QSARs in Europe and elsewhere in the world is
less widespread and formalized and is generally
on a local (national) level by individual agencies.
Future Outlook
Because of the perceived need to assess the
human health effects of a large number of
existing substances, it is likely that QSARs and
other computational approaches for predicting
human health effects will become increasingly
applied for the purposes of priority setting,
hazard assessment, and risk assessment. In the
cases of QSARs that are intended for hazard
and risk assessment purposes, it will be particu-
larly important to establish the limitations and
predictive capacities of the models. This can be
achieved only by proper validation under the
auspices of organizations or platforms that are
independent of both the QSAR developers and
the end users (industry and/or regulatory
authorities). In addition to the use of models
for regulatory assessment, the increased release
of confidential data for modeling is both a
necessity and more likely through initiatives
such as the U.S. FDA CRADA.
In the EU, the REACH system is likely to
have important implications for the develop-
ment, validation, and application of QSARs
and other computer-based approaches for pre-
dicting chemical toxicity. In particular, the EC
white paper (EC 2002) has envisaged that
assessments of one or more physicochemical,
toxicologic, and ecotoxicologic properties of up
to 30,100 existing chemicals, which are cur-
rently marketed in volumes greater than 1 met-
ric ton per year, will be required by the end of
2012. Furthermore, in its conclusions on the
white paper (Council of Ministers 2001), the
Environment Council of the European
Commission has called upon the commission 
. . . to explore ways in which chemicals of concern
can be identiﬁed to allow prioritisation for taking
action, developing clear and transparent screening
criteria, essential information requirements, and
exploring the use of chemical grouping and model-
ling techniques. . . . (Council Conclusion 37)
Given the limitations in the testing capac-
ity of EU industry, it seems likely that the
envisaged deadline for obtaining the required
information will only be met if QSAR
approaches are used wherever it is scientiﬁcally
feasible to do so. For example, QSAR models
could be used to prioritize chemicals for further
testing, to identify certain types of toxic hazard
(possibly in order to derogate from further test-
ing), or to provide estimates of toxic potency
for use in risk assessments.
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